膀胱内透明质酸(Cystistat®)膀胱扩张与单纯膀胱扩张治疗间质性膀胱炎的短期疗效:一项随机对照试验

Q4 Medicine
A. Farazi, M. Keshvari, M. Tavakkoli, M. Najaf Najafi, A. Ebrahimi, Anahita Ghazaghi, Maryam Noorbakhsh, Hamidreza Rahimi
{"title":"膀胱内透明质酸(Cystistat®)膀胱扩张与单纯膀胱扩张治疗间质性膀胱炎的短期疗效:一项随机对照试验","authors":"A. Farazi, M. Keshvari, M. Tavakkoli, M. Najaf Najafi, A. Ebrahimi, Anahita Ghazaghi, Maryam Noorbakhsh, Hamidreza Rahimi","doi":"10.5812/numonthly-129810","DOIUrl":null,"url":null,"abstract":"Background: Interstitial cystitis (IC) is a chronic, debilitating bladder disease that primarily affects middle-aged women and significantly affects their quality of life. Bladder hydrodistention is the usual therapeutic and diagnostic procedure, but symptoms tend to relapse. Adding hyaluronic acid to hydrodistention has been shown to improve the outcomes. Objectives: To compare the therapeutic effects of bladder hydrodistention alone or with intravesical cystistat (40 mg of sodium hyaluronate in a 50 mL vial) in treating IC/bladder pain syndrome (IC/BPS). Methods: This randomized controlled clinical trial was conducted in Imam Reza Hospital of Mashhad in 2017. Twenty-four female IC/BPS patients were selected using clinical examinations and the O`Leary-Sant IC questionnaire to evaluate treatment effects. Patients with a history of other diseases related to the urogenital system and urination frequency less than eight times a day were excluded. The control group (n = 12) underwent hydrodistention under general anesthesia, and the intervention group (n = 12) received intravesical cystistat in addition to hydrodistention weekly for four weeks, followed by monthly for two months. Results: In the control group, the mean baseline score of the questionnaire was 33.2 ± 1.9 and reached 33.9 ± 2.6 after three months, showing no significant change. In the intervention group, the mean baseline score of the questionnaire was 32.6 ± 3.6 and reached 6.4 ± 12.4 at the end of the third month, which indicates a significantly better improvement (P < 0.001). In this study, the disease symptoms resolved in 83.3% of the intervention group after three months of treatment, while the controls did not improve. Conclusions: Based on our study, intravesical instillation of cystistat is effective in treating patients with IC/BPS and has significantly better effects than hydrodistention alone.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Short-term Outcomes of Hydrodistention with Intravesical Hyaluronic Acid (Cystistat®) Versus Hydrodistention Alone for Treating Interstitial Cystitis: A Randomized Controlled Trial\",\"authors\":\"A. Farazi, M. Keshvari, M. Tavakkoli, M. Najaf Najafi, A. Ebrahimi, Anahita Ghazaghi, Maryam Noorbakhsh, Hamidreza Rahimi\",\"doi\":\"10.5812/numonthly-129810\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Interstitial cystitis (IC) is a chronic, debilitating bladder disease that primarily affects middle-aged women and significantly affects their quality of life. Bladder hydrodistention is the usual therapeutic and diagnostic procedure, but symptoms tend to relapse. Adding hyaluronic acid to hydrodistention has been shown to improve the outcomes. Objectives: To compare the therapeutic effects of bladder hydrodistention alone or with intravesical cystistat (40 mg of sodium hyaluronate in a 50 mL vial) in treating IC/bladder pain syndrome (IC/BPS). Methods: This randomized controlled clinical trial was conducted in Imam Reza Hospital of Mashhad in 2017. Twenty-four female IC/BPS patients were selected using clinical examinations and the O`Leary-Sant IC questionnaire to evaluate treatment effects. Patients with a history of other diseases related to the urogenital system and urination frequency less than eight times a day were excluded. The control group (n = 12) underwent hydrodistention under general anesthesia, and the intervention group (n = 12) received intravesical cystistat in addition to hydrodistention weekly for four weeks, followed by monthly for two months. Results: In the control group, the mean baseline score of the questionnaire was 33.2 ± 1.9 and reached 33.9 ± 2.6 after three months, showing no significant change. In the intervention group, the mean baseline score of the questionnaire was 32.6 ± 3.6 and reached 6.4 ± 12.4 at the end of the third month, which indicates a significantly better improvement (P < 0.001). In this study, the disease symptoms resolved in 83.3% of the intervention group after three months of treatment, while the controls did not improve. Conclusions: Based on our study, intravesical instillation of cystistat is effective in treating patients with IC/BPS and has significantly better effects than hydrodistention alone.\",\"PeriodicalId\":19466,\"journal\":{\"name\":\"Nephro-urology Monthly\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephro-urology Monthly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/numonthly-129810\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephro-urology Monthly","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/numonthly-129810","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:间质性膀胱炎(IC)是一种慢性、使人衰弱的膀胱疾病,主要影响中年妇女,并严重影响她们的生活质量。膀胱积水是常见的治疗和诊断程序,但症状往往会复发。添加透明质酸进行脱水已被证明可以改善效果。目的:比较膀胱水下压单独或与膀胱内胱氨酸盐(40mg透明质酸钠50mL小瓶)治疗IC/膀胱疼痛综合征(IC/BPS)的疗效。方法:本随机对照临床试验于2017年在马什哈德伊玛目礼萨医院进行。使用临床检查和O’Leary-Sant-IC问卷选择24名女性IC/BPS患者来评估治疗效果。排除有与泌尿生殖系统相关的其他疾病史且每天排尿次数少于8次的患者。对照组(n=12)在全身麻醉下接受膀胱内液体减压,干预组(n=2)除了每周接受液体减压外,还接受膀胱内胱氨酸盐,持续四周,然后每月接受,持续两个月。结果:对照组的问卷平均基线得分为33.2±1.9,三个月后达到33.9±2.6,无明显变化。在干预组中,问卷的平均基线得分为32.6±3.6,在第三个月底达到6.4±12.4,这表明有明显更好的改善(P<0.001)。在本研究中,83.3%的干预组在治疗三个月后疾病症状得到缓解,而对照组没有改善。结论:根据我们的研究,膀胱内滴注胱氨酸盐对IC/BPS患者是有效的,并且其效果明显优于单独的水下滴注。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Short-term Outcomes of Hydrodistention with Intravesical Hyaluronic Acid (Cystistat®) Versus Hydrodistention Alone for Treating Interstitial Cystitis: A Randomized Controlled Trial
Background: Interstitial cystitis (IC) is a chronic, debilitating bladder disease that primarily affects middle-aged women and significantly affects their quality of life. Bladder hydrodistention is the usual therapeutic and diagnostic procedure, but symptoms tend to relapse. Adding hyaluronic acid to hydrodistention has been shown to improve the outcomes. Objectives: To compare the therapeutic effects of bladder hydrodistention alone or with intravesical cystistat (40 mg of sodium hyaluronate in a 50 mL vial) in treating IC/bladder pain syndrome (IC/BPS). Methods: This randomized controlled clinical trial was conducted in Imam Reza Hospital of Mashhad in 2017. Twenty-four female IC/BPS patients were selected using clinical examinations and the O`Leary-Sant IC questionnaire to evaluate treatment effects. Patients with a history of other diseases related to the urogenital system and urination frequency less than eight times a day were excluded. The control group (n = 12) underwent hydrodistention under general anesthesia, and the intervention group (n = 12) received intravesical cystistat in addition to hydrodistention weekly for four weeks, followed by monthly for two months. Results: In the control group, the mean baseline score of the questionnaire was 33.2 ± 1.9 and reached 33.9 ± 2.6 after three months, showing no significant change. In the intervention group, the mean baseline score of the questionnaire was 32.6 ± 3.6 and reached 6.4 ± 12.4 at the end of the third month, which indicates a significantly better improvement (P < 0.001). In this study, the disease symptoms resolved in 83.3% of the intervention group after three months of treatment, while the controls did not improve. Conclusions: Based on our study, intravesical instillation of cystistat is effective in treating patients with IC/BPS and has significantly better effects than hydrodistention alone.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nephro-urology Monthly
Nephro-urology Monthly Medicine-Urology
CiteScore
0.40
自引率
0.00%
发文量
26
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信